Michael P. DiGiovanna
- Oncology top 1%
- Molecular Biology top 10%
- Cancer Research top 2%
- Radiology, Nuclear Medicine and Imaging top 2%
- Surgery top 10%
- Co-authors
- David F. SternDonald R. LanninLajos PusztaiDarryl CarterBrigid K. KilleleaMaysa Abu‐KhalafBruce G. HafftyTara Sanft
- Topics
- HER2/EGFR in Cancer Research (32 papers)Breast Cancer Treatment Studies (23 papers)Cancer Treatment and Pharmacology (18 papers)
- Partner nations
- United StatesCanadaPoland
In The Last Decade
Michael P. DiGiovanna
73 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Oncology 1.7k
- Molecular Biology 805
- Cancer Research 727
- Radiology, Nuclear Medicine and Imaging 633
- Surgery 388
Countries citing papers authored by Michael P. DiGiovanna
This map shows the geographic impact of Michael P. DiGiovanna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. DiGiovanna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. DiGiovanna more than expected).
Fields of papers citing papers by Michael P. DiGiovanna
This network shows the impact of papers produced by Michael P. DiGiovanna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. DiGiovanna. The network helps show where Michael P. DiGiovanna may publish in the future.
Co-authorship network of co-authors of Michael P. DiGiovanna
This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. DiGiovanna. A scholar is included among the top collaborators of Michael P. DiGiovanna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. DiGiovanna. Michael P. DiGiovanna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 14 | |
| 2 | 57 | |
| 3 | 36 | |
| 4 | 14 | |
| 5 | 30 | |
| 6 | 17 | |
| 7 | A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25). | 1 |
| 8 | 8 | |
| 9 | 67 | |
| 10 | 43 | |
| 11 | 28 | |
| 12 | 49 | |
| 13 | 7 | |
| 14 | Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells | 6 |
| 15 | 193 | |
| 16 | 8 | |
| 17 | Synergistic interaction between all-trans retinoic acid, Herceptin, and tamoxifen in BT-474 human breast cancer cells. | 1 |
| 18 | 209 | |
| 19 | 7 | |
| 20 | 47 |
About Michael P. DiGiovanna
Michael P. DiGiovanna is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 74 papers that have together received 2.8k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (32 papers), Breast Cancer Treatment Studies (23 papers) and Cancer Treatment and Pharmacology (18 papers). The work is most often cited by research in Oncology (1.7k citations), Cancer Research (727 citations) and Radiology, Nuclear Medicine and Imaging (633 citations). Michael P. DiGiovanna has collaborated with scholars based in United States, Canada and Poland. Frequent co-authors include David F. Stern, Donald R. Lannin, Lajos Pusztai, Darryl Carter, Brigid K. Killelea, Maysa Abu‐Khalaf, Bruce G. Haffty, Tara Sanft, Anees B. Chagpar and Ann D. Thor. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.